Valuation
- Market cap
- 28,887,000
- Revenue TTM
- $0
- Net income TTM
- $-36,120,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 332,600
- Avg volume
- 1,699,104
- Day's range
- $0.30 – $0.32
- Shares out
- 91,879,000
- Stochastic %K
- 13%
- Beta
- 1.72
- Analysts
- Strong Sell
- Price target
- $4.88
Company profile
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6...
Show more
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 267 225 7416
- Website
- https://www.contexttherapeutics.com
- Address
- 2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States
Latest news
No headlines yet.
